Owing to production problems and concern over rare side effects, adoption of the Johnson & Johnson COVID-19 vaccine in the U.S. has slowed. The single-dose vaccine has comprised only 4% of the doses administered so far in the U.S. (The New York Times)

Athira Pharma, a biotech developing treatments for neurodegenerative diseases such as Alzheimer’s, has placed chief executive Leen Kawas on temporary leave. Her former university is investigating allegations that, during her time as a graduate student, she published papers containing altered images. (STAT)

A World Health Organization official said that the Delta variant of COVID-19 is becoming globally dominant. Chief scientist Soumya Swaminathan cited the variant’s increased transmissability. (Reuters)

As Brazil’s COVID-19 death total nears 500,000, the country is reckoning with choices it made over the course of the last 15 months. Some 2,000 people per day are still dying from the virus in the country, which ranks behind only the U.S. in total number of deaths. (Associated Press)

ALS patients and advocacy groups continue to chafe at the Food and Drug Administration’s decision to approve Biogen’s Alzheimer’s disease drug Aduhelm. They are questioning why a drug with questionable efficacy has passed agency muster while experimental treatments for ALS have not received the same consideration. (Endpoints News)